ClinicalTrials.gov
ClinicalTrials.gov Menu

Adjuvant BEmiparin in Small Cell Lung Carcinoma (ABEL STUDY)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00324558
Recruitment Status : Terminated (Sponsor stopped due to difficulties to recruit 130 patients required by protocol)
First Posted : May 11, 2006
Last Update Posted : June 8, 2012
Sponsor:
Information provided by (Responsible Party):
Clinica Universidad de Navarra, Universidad de Navarra

May 9, 2006
May 11, 2006
June 8, 2012
June 2005
February 2010   (Final data collection date for primary outcome measure)
  • efficacy: progression-free survival in months (measurements of the size of the effect will be done using the Kaplan Meier method and the difference between the means of this time) [ Time Frame: efficacy ]
  • safety: will be the incidence, during randomized treatment period (from day 1 to the last day of treatment + 7 days), of major bleedings. [ Time Frame: safety ]
  • efficacy: progression-free survival in months (measurements of the size of the effect will be done using the Kaplan Meier method and the difference between the means of this time)
  • safety: will be the incidence, during randomized treatment period (from day 1 to the last day of treatment + 7 days), of major bleedings.
Complete list of historical versions of study NCT00324558 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Adjuvant BEmiparin in Small Cell Lung Carcinoma (ABEL STUDY)
Multicenter, Randomized, Open and Sequential Study to Evaluate the Efficacy and Safety of Bemiparin Administration on the Response to Treatment in Patients Diagnosed With Limited Small Cell Lung Cancer

Main objective:

To evaluate whether the subcutaneous administration (sc) of Bemiparin (3,500 UI/day) for 26 weeks, starting on the first day of chemotherapy (CT), delays tumoral spread and increases progression-free survival.

Secondary objectives:

To evaluate whether the subcutaneous administration (sc) of Bemiparin (3,500 UI/day) for 26 weeks, starting with the onset of chemotherapy, increases global survival, improving the response rates to treatment with CT + RT (radiotherapy) and reduces the incidence of venous thromboembolism (VTE).

There is clinical evidence indicative of the beneficial effects of heparin in the evolution of patients with cancer. Apart from the studies that in an indirect way demonstrated an increase in the survival of oncological patients who, because of presenting a venous thromboembolism episode, were treated with low molecular weight heparin (LMWH) in comparison with those treated with non-fractionated heparin; direct actions were also demonstrated from the use of heparin in the survival and tumour progression. The administration of LMWH together with Chemotherapy has been proved to increase the survival of patients diagnosed of cancer of the pancreas in relation to those only treated with chemotherapy. An increase in the global survival of advanced solid tumours, with no thromboembolic disease,has also been showed.

All this suggests that an improvement in the survival of patients is observed when heparin is added to the usual anti-tumour treatment, especially to those without spread disease, and this effect seems to be independent of the protection against the thromboembolic complications.

Interventional
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Carcinoma, Small Cell
Drug: Bemiparin
subcutaneous administration (sc) of Bemiparin (3,500 UI/day) for 26 weeks, starting on the first day of chemotherapy (CT)
  • Experimental: 1
    Bemiparin 3,500 IU
    Intervention: Drug: Bemiparin
  • No Intervention: Control
Lecumberri R, López Vivanco G, Font A, González Billalabeitia E, Gúrpide A, Gómez Codina J, Isla D, Galán A, Bover I, Domine M, Vicente V, Rosell R, Rocha E. Adjuvant therapy with bemiparin in patients with limited-stage small cell lung cancer: results from the ABEL study. Thromb Res. 2013;132(6):666-70. doi: 10.1016/j.thromres.2013.09.026. Epub 2013 Sep 27.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
39
130
September 2010
February 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Patients 18 years old or older, of either sex, with a diagnosis of limited small cell lung cancer.
  2. Patients with an ECOG functional state less than or equal to 2.
  3. Informed consent to participate in the study.
  4. Patients with a platelet count above 100,000/microlitre with no hemorrhagic symptomatology.

Exclusion Criteria:

  1. Curative or palliative surgery as the initial treatment of their neoplastic condition.
  2. Patients with an active hemorrhage in the past two months, organic lesions susceptible to bleeding (e.g. active peptic ulcer, hemorrhagic cerebrovascular accident, aneurysms), history of clinically evident hemorrhagic episodes, major surgery in the past month, outstanding clinically hemoptysis or an increased risk of bleeding due to any homeostatic alteration that contraindicates anticoagulant therapy.
  3. Known hypersensitivity to LMWH, heparin or substances of porcine origin.
  4. Patients with hypersensitivity to the chemotherapeutic agents used in this protocol that makes it impossible to use the antitumoral regime indicated in this protocol (cisplatin or carboplatin and etoposide), i.e. hypersensitivity to cisplatin and carboplatin or hypersensitivity to etoposide.
  5. Patients with congenital or acquired bleeding diathesis.
  6. Damage to/ or surgical interventions of the central nervous system, eyes and ears within the past 6 months.
  7. Acute bacterial endocarditis or slow endocarditis.
  8. Patients with a history of heparin-associated thrombocytopenia or with a current platelet count < 100,000/mm3
  9. Patients with severe renal failure (serum creatinine over 2 mg/dl) or hepatic insufficiency (with values of AST and/or ALT > 5 times the normal value established in the reference range of the local hospital laboratory).
  10. Severe arterial hypertension (systolic blood pressure over 200 mmHg and/or diastolic blood pressure above 120 mmHg).
  11. Women who are pregnant or breast-feeding, or with the possibility of becoming pregnant during the study.
  12. Patients with suspected inability/or inability to comply with treatment and/or complete the study.
  13. Patients who are participating in another clinical trial or have done so in the past 30 days.
  14. Patients with a life expectancy less than 3 months.
  15. Patients on treatment with anticoagulants or who have been on treatment during three months before the diagnosis of the tumor.
Sexes Eligible for Study: All
18 Years and older   (Adult, Older Adult)
No
Contact information is only displayed when the study is recruiting subjects
Spain
 
 
NCT00324558
ICT-BEM-2004-01
2004-004722-27 (Nº EudraCT)
No
Not Provided
Not Provided
Clinica Universidad de Navarra, Universidad de Navarra
Clinica Universidad de Navarra, Universidad de Navarra
Not Provided
Principal Investigator: Alfonso Gúrpide, MD Clínica Universitaria de Navarra
Principal Investigator: Enrique Gonzalez, MD Hospital General Universitario Morales Meseguer
Principal Investigator: Guillermo López, MD Hopspital de Cruces, Baracaldo (Vizcaya)
Principal Investigator: César Rodríguez, MD Hospital Clínico de Salamanca
Principal Investigator: Juan C. Torrego, MD Hospital del Río Hortega
Principal Investigator: José Gómez, MD HOSPITAL LA FE VALENCIA
Principal Investigator: Albert Font, MD Germans Trias i Pujol Hospital
Principal Investigator: Isidoro C. Barneto, MD Hospital Reina Sofia (Córdoba)
Principal Investigator: Antonio Lorenzo, MD Hospital de Puerto Real (Cádiz)
Principal Investigator: Dolores Isla, MD Hospital Clínico Lozano Blesa (Zaragoza)
Study Director: Eduardo Rocha, MD Clínica Universitaria de Navarra
Principal Investigator: Bartolomeu Massuti, MD Hospital General Universitario de Alicante
Principal Investigator: Antonio Galán Brotons, MD Hospital de Sagunto
Principal Investigator: Ana Blasco Cordellat, MD Hospital General Universitario de Valencia
Principal Investigator: Juan J. Bretón, MD Hospital Universitario Carlos Haya
Principal Investigator: Isabel Bover Barceló, MD Hospital Son Llàtzer
Principal Investigator: Nuria Viñolas, MD Hospital Clinic i Provincial de Barcelona
Clinica Universidad de Navarra, Universidad de Navarra
June 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP